Cargando…

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

Insufficient eradication capacity and dysfunction are common occurrences in T cells that characterize cancer immunotherapy failure. De novo DNA methylation promotes T cell exhaustion, whereas methylation inhibition enhances T cell rejuvenation in vivo. Decitabine, a DNA methyltransferase inhibitor a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yao, Tong, Chuan, Dai, Hanren, Wu, Zhiqiang, Han, Xiao, Guo, Yelei, Chen, Deyun, Wei, Jianshu, Ti, Dongdong, Liu, Zongzhi, Mei, Qian, Li, Xiang, Dong, Liang, Nie, Jing, Zhang, Yajing, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814040/ https://www.ncbi.nlm.nih.gov/pubmed/33462245 http://dx.doi.org/10.1038/s41467-020-20696-x

Ejemplares similares

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

CD58 loss in tumor cells confers functional impairment of CAR T cells
por: Yan, Xin, et al.
Publicado: (2022)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
por: Dai, Hanren, et al.
Publicado: (2020)

Optimized collaboration of the first and third signals endows robust activity to T cells within the immunocompetent tumor microenvironment
por: Wei, Jianshu, et al.
Publicado: (2023)

Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
por: Wang, Yao, et al.
Publicado: (2018)

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
por: Song, Yanjing, et al.
Publicado: (2017)

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
por: Grunewald, Camilla M., et al.
Publicado: (2021)

Inducing immunogenic cell death in immuno-oncological therapies
por: Ti, Dongdong, et al.
Publicado: (2022)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
por: Feng, Kaichao, et al.
Publicado: (2017)

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8(+) progenitor exhausted T cell expansion in tumor models
por: Li, Xiang, et al.
Publicado: (2023)

A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
por: Gore, Lia, et al.
Publicado: (2017)

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production
por: Guo, Yelei, et al.
Publicado: (2023)

DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
por: Nie, Jing, et al.
Publicado: (2016)

Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
por: Qu, Changju, et al.
Publicado: (2022)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
por: You, Liangshun, et al.
Publicado: (2020)

Identification of a Novel p53 Modulator Endowed with Antitumoural and Antibacterial Activity through a Scaffold Repurposing Approach
por: Nuti, Elisa, et al.
Publicado: (2022)

CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
por: Guo, Yelei, et al.
Publicado: (2022)

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
por: Fu, Wenyan, et al.
Publicado: (2019)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
por: Alvanou, Maria, et al.
Publicado: (2023)

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
por: Jo, Sumin, et al.
Publicado: (2022)

Endowments
Publicado: (1894)

Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
por: Guo, Yelei, et al.
Publicado: (2021)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
por: Liu, Zongzhi, et al.
Publicado: (2023)

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
por: Fan, Hui, et al.
Publicado: (2014)

The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
por: Wei, Jianshu, et al.
Publicado: (2020)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
por: Li, Hongwen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_945et2hqi6nj15p6ngr030982i